Liposomal irinotecan+5-FU/LV + bevacizumab for second-line treatment of metastatic colorectal cancer (IRIS): A prospective, multi-center, single-arm clinical study
第一作者机构:[1]Hebei Med Univ, Hosp 4, Dept Gen Surg 2, Shijiazhuang, Hebei, Peoples R China
通讯机构:[11]Hebei Med Univ, Dept Gen Surg, Dept Gen Surg 2, Hosp 2,Hosp 4,Hebei Prov Key Lab Gastrointestinal, Shijiazhuang, Hebei, Peoples R China
推荐引用方式(GB/T 7714):
Hu X.,Jiang B.,Lu H.,et al.Liposomal irinotecan+5-FU/LV + bevacizumab for second-line treatment of metastatic colorectal cancer (IRIS): A prospective, multi-center, single-arm clinical study[J].ANNALS OF ONCOLOGY.2024,35:S1440-S1440.doi:10.1016/j.annonc.2024.10.118.
APA:
Hu, X.,Jiang, B.,Lu, H.,Niu, W.,Ma, H....&Wang, G..(2024).Liposomal irinotecan+5-FU/LV + bevacizumab for second-line treatment of metastatic colorectal cancer (IRIS): A prospective, multi-center, single-arm clinical study.ANNALS OF ONCOLOGY,35,
MLA:
Hu, X.,et al."Liposomal irinotecan+5-FU/LV + bevacizumab for second-line treatment of metastatic colorectal cancer (IRIS): A prospective, multi-center, single-arm clinical study".ANNALS OF ONCOLOGY 35.(2024):S1440-S1440